Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

09-01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI

Market Cap	63.66B 54.92B 51.73B 47.14B 88.11B 6,014B 88.77B 612B 238B 3,075B 239B 234B 10,100B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 69.85B 65.8B 59.95B 112B 7,648B 113B 779B 302B 3,910B 304B 297B 12,845B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

09-01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
30/06/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
19/10/24	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
27/08/24	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation : Allergan plc

Latest news : Allergan plc

Press Releases : Allergan plc

News in other languages : Allergan plc

Managers and Directors : Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	01/12/2016
Robert Michael PSD	President	55	08/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	08/05/2020
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/8/20 A	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
5/8/20 A	Adriane Brown	Issuer sale	Director	2,916	0.0009%
5/8/20 A	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	+0.01%	-2.47%	+57.79%	+108.23%	1,034B
JOHNSON & JOHNSON	+1.48%	+1.93%	+54.56%	+71.49%	663B
ABBVIE INC.	+0.67%	-0.45%	+23.50%	+76.60%	462B
ROCHE HOLDING AG	+2.52%	-1.98%	+32.39%	+38.48%	344B
NOVARTIS AG	+0.10%	+5.07%	+27.05%	+47.10%	307B
ASTRAZENECA PLC	+2.23%	+0.65%	-0.14%	+14.06%	251B
AMGEN INC.	+1.08%	+0.57%	+54.34%	+72.51%	239B
NOVO NORDISK A/S	+2.35%	+4.01%	-15.78%	-53.14%	207B
GILEAD SCIENCES, INC.	-0.21%	+1.03%	+32.74%	+95.19%	186B
Average	+0.63%	-0.45%	+29.61%	+52.28%	375.7B
Weighted average by Cap.	+0.57%	-0.80%	+38.46%	+67.69%

	2018	2019
Net sales	15.79B 13.62B 12.83B 11.69B 21.85B 1,491B 22.01B 152B 58.95B 762B 59.28B 57.99B 2,505B	16.09B 13.88B 13.08B 11.91B 22.27B 1,520B 22.43B 155B 60.08B 777B 60.42B 59.09B 2,553B
Net income	-5.1B -4.4B -4.14B -3.77B -7.05B -481B -7.11B -49.03B -19.03B -246B -19.14B -18.72B -809B	-5.27B -4.55B -4.28B -3.9B -7.3B -498B -7.35B -50.71B -19.68B -255B -19.79B -19.36B -836B
Net Debt	21.89B 18.88B 17.79B 16.21B 30.3B 2,068B 30.52B 211B 81.74B 1,057B 82.2B 80.4B 3,473B	17.3B 14.93B 14.06B 12.81B 23.95B 1,635B 24.13B 166B 64.62B 836B 64.98B 63.56B 2,745B